TAVI Adoption in Elderly Populations | Market Intelligence

Description

List of Tables

Transcatheter aortic valve implantation changed the treatment of aortic stenosis from an open-chest decision into a catheterization-lab decision, and nowhere does that matter more than in Japan, where the treated population is the oldest in the world and surgical risk concentrates accordingly. Procedure volumes have grown year on year, the center network has expanded under a certification system, and the treated population is shifting steadily toward older and frailer patients. The technology question that now dominates the field is how far down the risk spectrum TAVI should extend, and who decides.

The debate is genuinely open. European guidelines now recommend transcatheter treatment from the mid-seventies, pulling the eligibility frontier into territory where Japan's surgical outcomes are strong and its surgeons influential. Low-risk expansion would multiply the addressable population but collides with durability questions that registry data have not yet answered over the relevant horizons. Dialysis patients, a disproportionately large group in Japan, present calcification patterns and risk profiles that complicate both approaches, and the 2026 guidance from Japanese cardiovascular-thoracic societies addresses them directly. Meanwhile platform competition, Edwards and Medtronic at the core, Abbott, Boston Scientific, and a wave of Chinese and Indian challengers around the edges, plays out inside a reimbursement and center-certification structure that shapes what can actually be used.

This report maps the adoption system. It covers procedure-volume structure and center concentration under the Japanese certification framework; the risk-stratification and heart-team decision process; the low-risk expansion debate and the guideline positions that frame it; dialysis-patient risk modeling including the 2026 society guidance; and the device landscape platform by platform, from Sapien and Evolut through Navitor and Acurate to JenaValve, Venus Medtech, Peijia, MicroPort, Meril, and New Valve Technology, with Terumo's access-device position alongside. Registry infrastructure, including Japan's national TAVI registry and the OCEAN-TAVI collaboration, is treated as market infrastructure. International chapters benchmark adoption and pricing across the US, EU5, and China.

The report serves structural-heart franchise teams at incumbent and challenger manufacturers, hospital systems planning heart-team investment, dialysis and cardiology networks managing referral flows, and investors tracking the category. It is organized so that clinical-governance, device, and economics readers can each extract a coherent account.

Scope and Coverage

The report covers TAVI adoption structure, center certification, patient selection, device platforms, and reimbursement across the US, EU5, Japan, and China, including the low-risk expansion and dialysis-patient debates. Surgical valve replacement is covered as the comparator pathway. Outcome results are referenced only as the subjects of registry programs, not reported.

Report Highlights

Procedure-volume structure and center concentration under Japan's certification system
Heart-team decision mechanics and risk-stratification practice
Low-risk expansion debate: guideline positions and durability evidence agenda
Dialysis-patient risk modeling and the 2026 society guidance
Platform-by-platform device landscape including Chinese and Indian challengers
NHI reimbursement structure and center economics for TAVI programs

Product Code: JPH-012

Table of Content

1. Executive Summary

2. TAVI Adoption in Elderly Populations: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Edwards Lifesciences (US) - Sapien balloon-expandable platform family in Japan
Medtronic (US) - Evolut self-expanding platform family
Abbott (US) - Navitor valve within the structural-heart portfolio
Boston Scientific (US) - Acurate neo2/Prime valve
JenaValve (DE) - Trilogy system for aortic-regurgitation indications
MicroPort (CN) - VitaFlow TAVI line from China
Peijia Medical (CN) - TaurusElite and TaurusOne China TAVI platforms
Venus Medtech (CN) - VenusA valve family
Terumo (JP) - delivery sheaths and vascular-access devices used in Japanese TAVI
Meril Life Sciences (IN) - Myval platform expanding across Asia
New Valve Technology (CH) - Allegra self-expanding valve

Product Code: JPH-012

List of Tables

Table 1. Aortic stenosis in elderly populations: disease framework and treatment decision logic
Table 2. TAVI versus SAVR: procedural and governance comparison
Table 3. Heart-team structure requirements under Japanese certification rules
Table 4. Milestones in Japanese TAVI adoption and certification by year
Table 5. TAVI-treated population structure: age, risk profile, and access route
Table 6. Center-certification framework: facility and operator requirements
Table 7. Center-concentration structure and regional distribution
Table 8. Referral pathways from cardiology and dialysis networks to heart teams
Table 9. Bicuspid and complex-anatomy populations in Japanese practice
Table 10. Risk-stratification practice: scores, frailty assessment, and heart-team judgment
Table 11. Low-risk expansion debate: guideline positions from ESC and Japanese societies
Table 12. Durability evidence agenda: registry programs and follow-up structures
Table 13. Dialysis-patient risk modeling: JTCVS 2026 guidance structure
Table 14. Valve-in-valve and redo-procedure frameworks
Table 15. Peri-procedural management: anesthesia, access, and discharge protocols
Table 16. Edwards Sapien platform family: generations and Japan positioning
Table 17. Medtronic Evolut platform family: generations and Japan positioning
Table 18. Abbott Navitor within the structural-heart portfolio
Table 19. Boston Scientific Acurate neo2 and Prime platform status
Table 20. JenaValve Trilogy system and aortic-regurgitation indications
Table 21. Chinese platforms: Venus Medtech VenusA, Peijia TaurusElite and TaurusOne, MicroPort VitaFlow
Table 22. Meril Myval and New Valve Technology Allegra: additional challenger platforms
Table 23. Terumo delivery sheaths and vascular-access devices in Japanese TAVI
Table 24. Cerebral-protection, closure, and imaging adjunct ecosystem
Table 25. PMDA approval pathway for transcatheter heart valves
Table 26. FDA and EMA pathway comparison and indication-label differences
Table 27. NMPA pathway and the Chinese domestic-platform context
Table 28. Registry obligations: Japan national TAVI registry participation requirements
Table 29. NHI reimbursement structure for TAVI devices and procedures
Table 30. Center economics: fixed-cost and case-volume conditions for program viability
Table 31. US and EU5 payment structures for TAVI programs
Table 32. China payment environment and domestic-platform pricing
Table 33. Japan national TAVI registry: governance and data structure
Table 34. OCEAN-TAVI collaboration: study portfolio and publication program
Table 35. Edwards Lifesciences: structural-heart franchise and Japan organization
Table 36. Medtronic: structural-heart franchise and Japan organization
Table 37. Abbott and Boston Scientific: challenger positioning in Japan
Table 38. Chinese and Indian platform sponsors: Japan entry status and options
Table 39. JenaValve, Meril, and NVT: niche-platform strategies
Table 40. Terumo: access-device and distribution positions
Table 41. Hospital-system strategies for structural-heart investment
Table 42. Surgical-society and cardiology-society positions in the expansion debate
Table 43. Unmet needs: durability data gaps and dialysis-population evidence
Table 44. Center-network expansion options and their constraints
Table 45. Challenger-platform entry pathways into Japan
Table 46. Adjunct-device opportunities: access, protection, and imaging
Table 47. Training and proctoring infrastructure for center development
Table 48. Policy agenda: certification rules, reimbursement review points, and registry evolution
Table 49. Report methodology: registry frameworks, device documentation, and interview base
Table 50. Glossary of devices, scores, and program terms

List of Figures

Figure 1. Aortic stenosis treatment decision framework
Figure 2. TAVI versus SAVR pathway comparison
Figure 3. Heart-team structure under Japanese certification
Figure 4. Japanese TAVI adoption timeline
Figure 5. Treated-population structure framework
Figure 6. Center-certification requirement map
Figure 7. Center-concentration and regional distribution framework
Figure 8. Referral pathway map from cardiology and dialysis networks
Figure 9. Complex-anatomy population schematic
Figure 10. Risk-stratification workflow in heart-team practice
Figure 11. Low-risk expansion debate: guideline position map
Figure 12. Durability evidence agenda structure
Figure 13. Dialysis-patient risk-model framework under JTCVS 2026
Figure 14. Valve-in-valve and redo-procedure decision flow
Figure 15. Peri-procedural management pathway
Figure 16. Sapien platform generation map
Figure 17. Evolut platform generation map
Figure 18. Navitor portfolio position diagram
Figure 19. Acurate platform status map
Figure 20. Trilogy system and AR indication schematic
Figure 21. Chinese platform landscape: VenusA, Taurus, and VitaFlow
Figure 22. Myval and Allegra challenger positions
Figure 23. Terumo access-device role in Japanese TAVI
Figure 24. Adjunct ecosystem map: protection, closure, and imaging
Figure 25. PMDA pathway flow for transcatheter valves
Figure 26. FDA and EMA pathway and label comparison
Figure 27. NMPA pathway and domestic-platform context
Figure 28. Registry participation requirement flow
Figure 29. NHI reimbursement structure diagram for TAVI
Figure 30. Center-economics viability framework
Figure 31. US and EU5 payment structure comparison
Figure 32. China payment environment map
Figure 33. National TAVI registry governance structure
Figure 34. OCEAN-TAVI study portfolio map
Figure 35. Edwards Japan organization and franchise structure
Figure 36. Medtronic Japan organization and franchise structure
Figure 37. Abbott and Boston Scientific challenger positioning
Figure 38. Chinese and Indian sponsor Japan entry map
Figure 39. Niche-platform strategy diagram
Figure 40. Terumo access and distribution position map
Figure 41. Hospital structural-heart investment framework
Figure 42. Society position map in the expansion debate
Figure 43. Durability and dialysis evidence gap map
Figure 44. Center-network expansion constraint diagram
Figure 45. Challenger entry pathway flow into Japan
Figure 46. Adjunct-device opportunity map
Figure 47. Training and proctoring infrastructure diagram
Figure 48. Policy agenda map: certification, reimbursement, registry
Figure 49. Methodology flow: registries, documentation, interviews
Figure 50. Data cut-off and update cadence schematic

TAVI Adoption in Elderly Populations | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. TAVI Adoption in Elderly Populations: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures